Loading
companiesCompany
ImmunityBio
ImmunityBio makes Anktiva, the IL-15 superagonist approved with BCG for bladder cancer in 2024.
Also called: Altor BioScience
Overview
ImmunityBio, based in San Diego and listed as IBRX, makes Anktiva, or nogapendekin alfa inbakicept, the IL-15 superagonist approved with BCG for bladder cancer in 2024. The approval followed a long regulatory path that included a complete response letter in 2023, and the company also runs natural killer cell and vaccine programmes. OnCo links it to bladder and urothelial cancer, to the nogapendekin alfa inbakicept drug record, and to the idea of off-the-shelf natural killer cells to sweep up residual disease. Whether an IL-15 agonist can extend beyond BCG-unresponsive bladder cancer into other tumours is the open question its pipeline is built around. Anktiva has its own page.
Headquarters
San Diego, CA, US
Scorecard
All companies#179of 1244 companies, score 32
- approved products +6
- phase 3 +3
- phase 1/2 +1
- targets +4
- modalities +4
- regions +3
- registry trials +11
1 approved, 1 in phase 3, 1 earlier, 2 targets, 31 registry studies. Formula on the scorecards page.
Type
Biotech · IBRX
Stage
Public
Website
ApprovedIL-15 superagonist (intravesical, with BCG)
Nogapendekin alfa inbakicept · Anktiva
Nogapendekin alfa inbakicept is an engineered version of the immune-boosting protein IL-15, given with BCG into the bladder, approved in 2024 for early bladder cancer that BCG alone no longer controls.
Phase 2cell therapy (type not stated)
CD19 t-haNK is an experimental cell therapy whose type is not stated from ImmunityBio in phase 2 trials for hodgkin lymphoma, aimed at CD19.
Phase 3Albumin-binding small-molecule prodrug of doxorubicin, intravenous
Aldoxorubicin is doxorubicin, the workhorse chemotherapy nicknamed the red devil, attached to a linker that hitches it to the body's own albumin so more reaches the tumour and less reaches the heart; it beat doxorubicin in a randomised phase 2 sarcoma trial but missed the primary endpoint of its phase 3, and a new company is now trying to finish its development.
Similar pages
- Key paperFirst-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial
Shares Aldoxorubicin, Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma.
- TermBCG-unresponsive
Shares QUILT 3.032, Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
- PersonSant P. Chawla
Shares Aldoxorubicin, Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma.
- CompanyGemini Therapeutics
Shares Aldoxorubicin, Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma.
- InstitutionSarcoma Oncology Center
Shares Aldoxorubicin, Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma.
- TechnologyCytokines & engineered cytokines
Shares QUILT 3.032, A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P, N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma, Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In.
- TreatmentIntravesical BCG
Shares QUILT 3.032, Bladder & urothelial cancer.
- TreatmentValrubicin
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
cancers
fronts
drugs
Phase 3Albumin-binding small-molecule prodrug of doxorubicin, intravenous
Phase 2cell therapy (type not stated)
ApprovedIL-15 superagonist (intravesical, with BCG)
Nogapendekin alfa inbakicept · Anktiva
trials
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In PA Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerAldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcomaClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InCombination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerN-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaQUILT 3.032QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsStudy of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma